Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Consensus Target Price of $9.60 According to Brokerages

Key Points

• Analyst sentiment is moderately positive: Six analysts give Entera Bio a consensus “Moderate Buy” rating, with an average 12-month price target of $9.60.
• Quarterly results missed expectations: Entera reported a loss of $0.11 per share, versus analysts’ expected loss of $0.06.
• Renaissance Technologies increased its Entera Bio holding by 338.4% in the first quarter, to 473,442 shares; institutional investors overall own 14.11% of the company.

Shares of Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.60.

A number of equities analysts have weighed in on the stock. Guggenheim began coverage on shares of Entera Bio in a report on Thursday, September 24th. They issued a "buy" rating and a $11.00 price target on the stock. Lifesci Capital began coverage on Entera Bio in a report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 price objective for the company. Wall Street Zen downgraded Entera Bio from a "sell" rating to a "strong sell" rating in a report on Saturday, November 7th. Leerink Partners started coverage on Entera Bio in a research report on Friday, September 18th. They issued an "outperform" rating and a $9.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on Entera Bio in a report on Tuesday, September 22nd. They issued an "overweight" rating on the stock.

Entera Bio Price Performance

ENTX opened at $3.22 on Friday. Entera Bio has a 12 month low of $0.91 and a 12 month high of $4.20. The business has a 50-day moving average of $2.90 and a two-hundred day moving average of $1.98. The stock has a market capitalization of $560.73 million, a price-to-earnings ratio of -8.26 and a beta of 1.48.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Equities research analysts anticipate that Entera Bio will post -0.40 earnings per share for the current year.

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Renaissance Technologies LLC grew its position in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 338.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 473,442 shares of the company's stock after purchasing an additional 365,441 shares during the period. Renaissance Technologies LLC owned approximately 0.96% of Entera Bio worth $526,000 as of its most recent SEC filing. Institutional investors own 14.11% of the company's stock.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company's development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.